Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.
about
Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerOptimizing the Clinical Use of VancomycinHigh prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis
P2860
Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Preferential emergence of redu ...... in an in vitro dynamic model.
@en
Preferential emergence of redu ...... in an in vitro dynamic model.
@nl
type
label
Preferential emergence of redu ...... in an in vitro dynamic model.
@en
Preferential emergence of redu ...... in an in vitro dynamic model.
@nl
prefLabel
Preferential emergence of redu ...... in an in vitro dynamic model.
@en
Preferential emergence of redu ...... in an in vitro dynamic model.
@nl
P2860
P50
P356
P1476
Preferential emergence of redu ...... in an in vitro dynamic model.
@en
P2093
Noha Alkurdi
Zhanni Weber
P2860
P304
P356
10.1128/AAC.01472-10
P407
P577
2011-04-18T00:00:00Z